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Background: Weight loss often leads to reductions in medication costs, particularly for weight-related conditions.
We aimed to evaluate changes in medication costs from an 18 month study of weight loss among patients
recruited from primary care.
Methods: Study participants (n = 79, average age = 56.3; 75.7 % female) with average BMI of 39.5 kg/m2, plus one
co-morbid condition of either diabetes/pre-diabetes, hypertension, abnormal cholesterol, or sleep apnea, were recruited
from 2 internal medicine practices. All participants received intensive behavioral and dietary treatment during months
0–6, including subsidized access to portion-controlled foods for weight loss. From months 7–18, all participants were
offered continued access to subsidized foods, and half of participants were randomly assigned to continue in-person visits
(“Intensified Maintenance”), while the other half received materials by mail or e-mail (“Standard Maintenance”). Medication
costs were evaluated at months 0, 6, and 18.
Results: Participants assigned to Intensified Maintenance maintained nearly all their lost weight, whereas those assigned
to Standard Maintenance regained weight. However, no significant differences in medication costs were observed within
or between groups during the 18 months of the trial. A reduction of nearly $30 per month (12.9 %) was
observed among all participants from month 0 to month 6 (active weight loss phase), but this difference did not
reach statistical significance.
Conclusions: A behavioral intervention that led to clinically significant weight loss did not lead to statistically significant
reductions in medication costs. Substantial variability in medication costs and lack of a systematic approach by the study
team to reduce medications may explain the lack of effect.
Trial registration: The trial was registered at (NCT01220089) on September 23, 2010.
Keywords: Obesity, Health care utilization, Medications, Clinical trialBackground
Obesity is arguably the greatest public health challenge
of the early 21st century in the U.S. and other developed
nations. Health care payers, both public and private, are
appropriately concerned about the large health care
costs of obesity [1, 2]. It is often assumed that reductions* Correspondence: adam.g.tsai@kp.org
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utilization, but this has not always been the case. For ex-
ample, in the Swedish Obese Subjects (SOS) study,
individuals who lost 15–25 % of their starting weight
after bariatric surgery had similar medication costs after
6 years of follow-up, compared to a control group
treated with diet and exercise and who lost a minimal
amount of weight [3]. Similarly, an analysis of patients
before and one year after weight loss surgery found no
reduction in the use of opioids for chronic pain, despite
an average reduction of 13 BMI units one year after surgeryis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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was observed.
Whether cost reductions are observed among individuals
losing weight may depend upon the type of intervention
that is used, as well as the characteristics of the intervention
participants and the degree of weight loss achieved.
Although weight loss surgery leads to dramatic weight
reduction, the high initial costs may take years to recoup.
At least two studies have demonstrated that medically
supervised low-calorie diets lead to substantial short term
reductions in medication costs, particularly for individuals
who had co-morbid conditions when they entered treat-
ment [5, 6]. The cost of a medically supervised low-calorie
diet program is substantially less than the cost of surgery
(at the current institution of the first author, a difference of
approximately 7 fold). Lesser but statistically significant
reductions in medication use have been observed in at least
two clinical trials of weight loss without the use of medically
supervised low-calorie diets [7, 8]. One of these two studies
was Look AHEAD, in which all participants had type 2
diabetes. Smaller reductions in health care expenditures
have been observed in workplace interventions [9]. It is
likely that individuals with higher medication utilization at
baseline (e.g., those with diabetes) will have the greatest
reductions in medication use and costs following clinically
significant weight loss.
Of the trials described above, only one trial was con-
ducted among patients encountered in primary care prac-
tice [8]. Thus, this study was undertaken to address the
existing gap in the literature of whether or not medication
costs are reduced among primary care patients who
undergo intensive lifestyle intervention for treatment of
obesity. We chose specifically to study the economic out-
comes of the intervention because economic outcomes of
obesity treatment, in addition to clinical outcomes, have
important implications for health care payers. Primary
care patients were the target population because of the
ongoing focus on improving the evaluation and treatment
of obesity in primary care settings in the U.S. [10].
Methods
We analyzed changes in medication costs during an
18 month clinical trial. The design, methods, and 6 month
outcomes of the study have been described previously [11].
Participants (n = 79) were recruited from two primary care
internal medicine practices at the University of Colorado.
Participants responded after receiving a recruitment letter.
They were initially screened by telephone for eligibility, and
then were evaluated in-person to ensure appropriateness for
participation in an extended behavioral weight loss interven-
tion. Participants had an average age of 56.3 years, an aver-
age BMI of 39.5 kg/m2, and were 75.7 % female. All
participants had at least one of the following co-morbidities:
diabetes/pre-diabetes (34 %), hypertension (58 %), abnormalcholesterol (65 %), or sleep apnea (30 %). Participants did
not have to be taking medication for the weight-related con-
dition to be eligible. Among all participants, the average
number of weight-related co-morbidities was 1.9.
All participants received intensive behavioral treatment
and subsidized access to portion-controlled foods for
weight loss during the first 6 months. Thus, months 0 to 6
formed the active weight loss phase of the trial. At month
6, participants were randomized to one of two treatment
conditions to help them maintain weight loss: “Standard
Maintenance” or “Intensified Maintenance.” All participants
continued to have access to subsidized portion-controlled
foods, but only those in the Intensified Maintenance group
continued in-person visits during months 7–18. A total of
84 participants were randomized to a treatment condition
at month 6, and of these, 79 completed 18 months of
treatment; thus, the attrition rate was 6.0 %. All partici-
pants lost a clinically significant amount of weight during
the first 6 months,9 and those assigned to Intensified
Maintenance kept off significantly more weight at
month 18 (data submitted for publication). The trial
was approved by the Colorado Multiple Institutional
Review Board (protocol #10-0719) and was registered at
www.clinicaltrials.gov (NCT01220089). All participants gave
informed consent prior to enrolling in the trial.
Medication names and doses were reviewed with study
participants at each of the major assessment points (month
0, month 6, and month 18). Costs were assigned to each
medication at the specific dose, using the ‘Big 4’ Federal
Supply Schedule, the pharmaceutical price list used by the
Coast Guard, the Department of Defense, the Public Health
Service, and the Veterans Administration [12]. We opted
not to use the average wholesale price from the “Red Book”,
as U.S. government reports have suggested that these prices
have been inflated by the pharmaceutical industry [13, 14].
In addition to testing changes in total medication costs,
we classified medications as being used for diabetes,
hypertension, or hyperlipidemia (i.e., a medication to treat
a weight-related condition), or as being used for another
condition. We hypothesized that if medication reductions
were observed, they would most likely be seen in
medications used to treat weight-related conditions.
We considered classification of any medication used
to treat a weight-related condition, but this was not a
clear separation (e.g., non-steroidal anti-inflammatory
medications and anti-depressants could potentially be
classified as being medications for weight-related condi-
tions, or could be classified as treating non weight-related
conditions). Finally, we conducted post-hoc analyses to
examine whether certain subsets of participants had
greater reductions in medication costs. Specifically, we
examined individuals with at least a 10 % weight loss, as
well as those with diabetes or hypertension, who were likely
to be taking the largest number of medications at baseline.
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variable was treatment group. We log-transformed cost
and used linear mixed models with random intercept
to account for the repeated outcome at three time
points (month 0, month 6, and month 18). Time was used
as an explanatory variable as well as an interaction
between time and treatment group to allow for differential
effect of the treatment group at each time point. The
smearing approach for back transforming the mean in the
log scale was used to obtain an estimate of the mean cost
in the original scale [15–17]. To obtain standard errors of
the mean in the original scale, the bootstrap method
with 2000 samples (with replacement) was used. As
the distribution of the differences of cost in the original
scale seemed fairly symmetric, p values were obtained
assuming a normal distribution for the empirical distribu-
tion of the mean estimate. Results based on the linear
mixed model were also obtained for cost of medications
non-weight-related as well as weight-related. All analyses
were conducted in the statistical program R [18]. We
present results below for re-transformed data, in order to
compare them to other published studies on this topic.
Analyses using median data showed similar results.
Costs are presented in 2013 U.S. dollar amounts.
Results
All participants lost a clinically significant amount of weight
during months 0–6. During months 7–18, the Standard
Maintenance group regained significantly more weight than
the Intensified Maintenance group (data submitted for
publication). Among the 84 individuals who were random-
ized at month 6, 79 completed the 18 month assessment.
Thus, the attrition rate was 6.0 %. No differences in age,





Change: Month 6- Month 18
Total cost −6.38(104.74)
Weight-related medicationsa, b −3.58(65.68)
Non-weight-related medicationsa, b −7.49(54.22)
Change: Month 0 – Month 18
Total cost −44.64(111.98)
Weight-related medicationsa, b −0.72(65.05)
Non-weight-related medicationsa, b −31.06(61.04)
a Data are presented as mean (se) in 2013 U.S. dollar amounts
a, b Medications for weight-related conditions are those for diabetes, hypertension,
† P values for Month 0 and change from Month 0 to Month 18 are not applicable s
at month 6)were observed between the 79 individuals who completed
the trial, as compared to the 5 who dropped out.
Of the 79 participants, 10 (12.7 %) took no medications at
baseline. At month 0, the average number of medications
per person was 3.49 ± 2.67, of which 1.68 ± 1.79 were for
weight-related conditions, and 1.81 ± 1.69 were for other
conditions. At month 6, the average number of medications
was 3.53 ± 2.65, of which 1.71 ± 1.83 were for weight-related
conditions and 1.82 ± 1.69 were for other conditions, re-
spectively. At month 18, the average number of medications
was 3.64 ± 2.72, of which 1.63 ± 1.73 were for weight-related
conditions and 2.01 ± 1.99 were for other conditions.
The overall results demonstrated no significant changes
in medication costs throughout the course of the trial.
During months 0–6 (the active weight loss phase),
mean medication costs among all study participants
were reduced from $229.08 to $199.54, a decrease of 12.9 %,
but this reduction did not reach statistical significance
(p = 0.34). During months 7–18 (the randomized phase),
there were no significant differences between the stand-
ard and intensified maintenance groups in medication
costs, either in total medication costs or whether medica-
tions were separated into weight-related or non-weight-
related categories (Table 1). Finally, post-hoc analyses of
participants with diabetes or hypertension and those with
at least a 10 % loss of initial weight showed no statistically
different differences (Table 2).
Discussion
In this analysis of medication cost changes from an
18 month clinical trial, we observed no significant changes
in medication costs, neither during the period of active
weight loss, nor between the two treatment groups for











ince these were not a priori planned comparisons (i.e., randomization occurred
Table 2 Changes in Medication Costs for Subgroupsa
Month 0 Month 6 Month 18 Change: Month 0 to
Month 6; p value
Change: Month 6 to
Month 18; p value
Change: Month 0 to
Month 18; p value
Diabetes (DM) 281.56 298.01 250.66 16.45 −47.36 −30.9
or Hypertension (59.89) (66.34) (56.42) (95.95); (97.21); (91.27);
(HTN) (n = 59) 0.57 0.31 0.37
10 % weight 232.78 215.38 213.48 −17.4 −1.9 −19.3
lossa, b (102.17) (92.43) (94.8) (150.74); (148.22); (160.1);
(n = 21) 0.45 0.49 0.45
DM or HTN and 256.05 235.86 233.43 −20.2 −2.43 −22.63
10 % weight (102.85) (93.18) (96.77) (151.39); (152.07); (161.71);
lossa, b (n = 19) 0.45 0.49 0.44
a Data are presented as mean (se) in 2013 U.S. dollar amounts
a, b Participants who lost at least 10 % of starting weight from month 0 to month 6
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of baseline weight and participants with diabetes or
hypertension also did not show significant differences,
possibly related to small sample size.
At least three reasons might explain why no differences
between groups were observed. First, the design of the
current study sought to prevent weight regain, which
limited our ability to detect differences between the two
study arms after randomization. Indeed, the difference
between the two groups in weight at 18 months was
3.7 kg, substantially smaller than the 8.1 % difference
between treatment and control groups in starting weight
(approximately 8 kg) seen after 1 year in the Look
AHEAD trial [19]. Second, nearly 13 % of participants took
no medications at all, limiting our ability to detect differ-
ences between groups, as most of these individuals had no
change in medication utilization throughout the trial. [A
post-hoc power calculation suggested that, with the effect
size and variance seen in the current trial, a sample size of
over 2,000 participants would have been required to ob-
serve statistically significant effects]. Third, unlike the
Look AHEAD Trial, where study physicians actively ad-
justed diabetes medications to prevent hypoglycemia as
participants lost weight, we left all medication changes to
participants’ personal physicians. We believe this third limi-
tation to be the most important, given the existing evidence
that obesity is not optimally managed in brief primary care
visits.
Although results from the current analysis were not
statistically significant, the reduction of $29.54 per
month in total medication costs during the active weight
loss phase (months 0–6) was similar in magnitude
compared to other studies. Redmon et al reported a
difference of $28 per month in medication costs from the
Look AHEAD Trial (n = 4,358, all with type 2 diabetes)
between the treatment and control groups after 1 year
(p < 0.001) [7]. Tsai et al reported a difference in medication
costs over two years in the POWER-UP Trial (n = 390,BMI of 30–49.9 kg/m2 and one other risk factor for cardio-
vascular disease) of $290 between treatment and control
groups (p < 0.05), which approximated to $12 per month
[8]. Collins and Anderson reported an annual savings of
$443 in medication costs (n = 32, all taking medication for
diabetes or hypertension) after completion of a very-low-
calorie diet (i.e., approximately $37 per month) [5].
Anderson and Jhaveri reported a reduction of $100 per
month in medication costs (n =183, including n = 100 with
severe obesity, and all taking medications for obesity-related
conditions) after a very-low-calorie diet, but only measured
medication usage for 20 weeks and did not follow patients
after completion of the program [6]. Wolf et al reported
that a RD intervention (n = 147, BMI ≥30 kg/m2 and with
type 2 diabetes) reduced inpatient costs substantially but
did not reduce medication costs [20].
Despite non-significant results, we believe that the lack of
cost differences in the current trial should not present a
barrier to implementation of obesity treatment in primary
care. Health care payers often expect treatment of chronic
diseases to be cost saving, but the reality is that very few in-
terventions in health care actually achieve this goal [21]. A
better metric of cost-effectiveness is cost per quality ad-
justed life year (QALY), which can be compared across all
kind of health care interventions. Full cost-effectiveness
analysis was beyond the scope of our resources in the
current trial, but has been conducted for other obesity
treatment interventions, including the Diabetes Prevention
Program [22–30].
Conclusions
In summary, in this 18 month clinical trial, we found no
significant changes in medication costs during weight loss
or weight loss maintenance. We believe that the population
in this trial was reasonably representative of patients
encountered in primary care. However, the disparate
results of this trial and of another economic analysis
of a primary care-based intervention [8] suggest the need
Tsai et al. BMC Obesity  (2015) 2:24 Page 5 of 5for more research in this area. The cost reductions seen
during the first 6 months are consistent with previous
literature, and thus, we believe these data are generalisable.
However, the lack of significance in the overall results may
not be generalisable to the broader population of primary
care patients, given that a similar magnitude of cost
reduction resulted in statistical significance in previous
trials with larger samples. Future studies should continue
to evaluate the economic benefits of weight reduction. In
doing so, studies should attempt to bridge the gap
between research and clinical practice and should help
patients achieve weight loss while enhancing quality and
coordination of medical care.
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